Oxurion NV Study

Oxurion NV / "A Phase 2, randomized, multicenter study to assess the dose level of multiple THR 149 injections and to evaluate the efficacy and safety of THR-149 versus aflibercept for the treatment of diabetic macular edema (DME)"

Purpose of the Study

The purpose of this study is to find the best dose of THR-149 and to see how well THR-149 treats diabetic macular edema compared to an approved drug called aflibercept. Aflibercept (Eylea®) has been approved by the FDA to treat diabetic macular edema (DME).

Basic Eligibility Criteria

  • 18 years of age or older.
  • Diagnosed to have diabetes.
  • Have Diabetic macular edema, for which you received treatment with anti-VEGFs (an available treatment for DME), but your vision did not really improve and you still have swelling in the back of your eye (macula).

How to Contact Us

Principal Investigator: Shree Kurup, MD
Study Contact: Leslie Castaneda | 216-844-2032